Table 6.
Processing conditions and designation of freshly fabricated nanoliposome formulations (i.e., F1 to F5) of EOs (CEO/TTO), and control (F6).
| Component | Function | F1 | F2 | F3 | F4 | F5 | F6 (Control) |
|---|---|---|---|---|---|---|---|
| Eos * (mM) | Bioactivesource | 6.2 | 4.9 | 3.7 | 2.5 | 1.2 | 0 |
| Soy lecithin (mg/mL) | Lipid | 10 | 10 | 10 | 10 | 10 | 10 |
| Tween 80® (M) | Surfactant | 0.076 | 0.076 | 0.076 | 0.076 | 0.076 | 0.076 |
| Cholesterol (mg/mL) | Lipid | 2 | 2 | 2 | 2 | 2 | 2 |
| PBS (mL (0.03 M)) | Saline buffer | 20 | 20 | 20 | 20 | 20 | 20 |
| Chloroform (mL) | Solvent | 10 | 10 | 10 | 10 | 10 | 10 |
* Represent CEO/TTO in respective samples.